Literature DB >> 33500707

Transplantation of autologous extracellular vesicles for cancer-specific targeting.

Alessandro Villa1, Mariangela Garofalo1, Daniela Crescenti1, Nicoletta Rizzi1, Electra Brunialti1, Andrea Vingiani2, Paolo Belotti3, Carlo Sposito3, Silvia Franzè4, Francesco Cilurzo4, Giancarlo Pruneri2, Camilla Recordati5, Chiara Giudice5, Alessia Giordano5, Monica Tortoreto6, Giangiacomo Beretta7, Damiano Stefanello5, Giacomo Manenti8, Nadia Zaffaroni6, Vincenzo Mazzaferro3, Paolo Ciana1.   

Abstract

Nano- and microsized extracellular vesicles (EVs) are naturally occurring cargo-bearing packages of regulatory macromolecules, and recent studies are increasingly showing that EVs are responsible for physiological intercellular communication. Nanoparticles encapsulating anti-tumor theranostics represent an attractive "exosome-interfering" strategy for cancer therapy.
Methods: Herein, by labeling plasma-derived EVs with indocyanine green (ICG) and following their biodistribution by in vivo and ex vivo imaging, we demonstrate the existence of nanoparticles with a highly selective cancer tropism in the blood of colorectal cancer (CRC) patients but not in that of healthy volunteers.
Results: In CRC patient-derived xenograft (PDX) mouse models, we show that transplanted EVs recognize tumors from the cognate nanoparticle-generating individual, suggesting the theranostic potential of autologous EVs encapsulating tumor-interfering molecules. In large canine breeds bearing spontaneous malignant skin and breast tumors, the same autologous EV transplantation protocol shows comparable safety and efficacy profiles. Conclusions: Our data show the existence of an untapped resource of intercellular communication present in the blood of cancer patients, which represents an efficient and highly biocompatible way to deliver molecules directly to the tumor with great precision. The novel EV-interfering approach proposed by our study may become a new research direction in the complex interplay of modern personalized cancer therapy. © The author(s).

Entities:  

Keywords:  biocompatible nanoparticles; cancer imaging; drug delivery; fluorescence; theranostic agents

Year:  2021        PMID: 33500707      PMCID: PMC7797692          DOI: 10.7150/thno.51344

Source DB:  PubMed          Journal:  Theranostics        ISSN: 1838-7640            Impact factor:   11.556


  41 in total

1.  Expanding on exosomes and ectosomes in cancer.

Authors:  Lorraine O'Driscoll
Journal:  N Engl J Med       Date:  2015-06-11       Impact factor: 91.245

2.  Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1.

Authors:  Fangjie Jiang; Qi Chen; Wei Wang; Yan Ling; Yan Yan; Pu Xia
Journal:  J Hepatol       Date:  2019-09-27       Impact factor: 25.083

3.  Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges.

Authors:  Mengjun Zhang; Xinlong Zang; Mingyue Wang; Zhen Li; Mingxi Qiao; Haiyang Hu; Dawei Chen
Journal:  J Mater Chem B       Date:  2019-03-13       Impact factor: 6.331

Review 4.  Subpopulations of extracellular vesicles and their therapeutic potential.

Authors:  Cecilia Lässer; Su Chul Jang; Jan Lötvall
Journal:  Mol Aspects Med       Date:  2018-02-16

5.  Assessment of plasma microvesicles to monitor pancreatic islet graft dysfunction: Beta cell- and leukocyte-derived microvesicles as specific features in a pilot longitudinal study.

Authors:  Lamia Amoura; Fatiha Z El-Ghazouani; Mohamad Kassem; Ali El Habhab; Guillaume Kreutter; Salah Sahraoui; Domenico Bosco; Nadia Jessel; Thierry Berney; Pierre-Yves Benhamou; Florence Toti; Laurence Kessler
Journal:  Am J Transplant       Date:  2019-08-26       Impact factor: 8.086

6.  Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment.

Authors:  M Garofalo; H Saari; P Somersalo; D Crescenti; L Kuryk; L Aksela; C Capasso; M Madetoja; K Koskinen; T Oksanen; A Mäkitie; M Jalasvuori; V Cerullo; P Ciana; M Yliperttula
Journal:  J Control Release       Date:  2018-06-01       Impact factor: 9.776

7.  Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.

Authors:  Giovanna Andreola; Licia Rivoltini; Chiara Castelli; Veronica Huber; Paola Perego; Paola Deho; Paola Squarcina; Paola Accornero; Francesco Lozupone; Luana Lugini; Annarita Stringaro; Agnese Molinari; Giuseppe Arancia; Massimo Gentile; Giorgio Parmiani; Stefano Fais
Journal:  J Exp Med       Date:  2002-05-20       Impact factor: 14.307

8.  A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer.

Authors:  Michael A Morse; Jennifer Garst; Takuya Osada; Shubi Khan; Amy Hobeika; Timothy M Clay; Nancy Valente; Revati Shreeniwas; Mary Ann Sutton; Alain Delcayre; Di-Hwei Hsu; Jean-Bernard Le Pecq; H Kim Lyerly
Journal:  J Transl Med       Date:  2005-02-21       Impact factor: 5.531

9.  Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography Results in Negative Surgical Margins and Decreased Local Recurrence in an Orthotopic Mouse Model of Osteosarcoma.

Authors:  Adel Mahjoub; Alejandro Morales-Restrepo; Mitchell S Fourman; Jonathan B Mandell; Lu Feiqi; Margaret L Hankins; Rebecca J Watters; Kurt R Weiss
Journal:  Ann Surg Oncol       Date:  2018-12-27       Impact factor: 5.344

10.  Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial.

Authors:  Bernard Escudier; Thierry Dorval; Nathalie Chaput; Fabrice André; Marie-Pierre Caby; Sophie Novault; Caroline Flament; Christophe Leboulaire; Christophe Borg; Sebastian Amigorena; Catherine Boccaccio; Christian Bonnerot; Olivier Dhellin; Mojgan Movassagh; Sophie Piperno; Caroline Robert; Vincent Serra; Nancy Valente; Jean-Bernard Le Pecq; Alain Spatz; Olivier Lantz; Thomas Tursz; Eric Angevin; Laurence Zitvogel
Journal:  J Transl Med       Date:  2005-03-02       Impact factor: 5.531

View more
  4 in total

Review 1.  Extracellular Vesicles as Promising Carriers in Drug Delivery: Considerations from a Cell Biologist's Perspective.

Authors:  Giona Pedrioli; Ester Piovesana; Elena Vacchi; Carolina Balbi
Journal:  Biology (Basel)       Date:  2021-04-27

Review 2.  Tumor-derived extracellular vesicles as messengers of natural products in cancer treatment.

Authors:  Yuanxin Xu; Kuanhan Feng; Huacong Zhao; Liuqing Di; Lei Wang; Ruoning Wang
Journal:  Theranostics       Date:  2022-01-16       Impact factor: 11.556

3.  Eliminating the original cargos of glioblastoma cell-derived small extracellular vesicles for efficient drug delivery to glioblastoma with improved biosafety.

Authors:  Yuhang Guo; Guowen Hu; Yuguo Xia; HaiYan Li; Ji Yuan; Juntao Zhang; Yu Chen; Hua Guo; Yunlong Yang; Yang Wang; Zhifeng Deng
Journal:  Bioact Mater       Date:  2022-03-16

4.  Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy.

Authors:  Yanwen Zheng; Fanhua Kong; Songyang Liu; Xi Liu; Dongni Pei; Xiongying Miao
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.